Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia - PubMed (original) (raw)
. 2003 Aug 15;102(4):1389-96.
doi: 10.1182/blood-2003-01-0019. Epub 2003 Apr 24.
Affiliations
- PMID: 12714493
- DOI: 10.1182/blood-2003-01-0019
Free article
Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia
Helmut Rainer Salih et al. Blood. 2003.
Free article
Abstract
NKG2D ligands (NKG2DLs) mark malignant cells for recognition by natural killer (NK) cells and cytotoxic T lymphocytes via the activating immunoreceptor NKG2D. This led to the hypothesis that NKG2DLs play a critical role in tumor immune surveillance. The human NKG2DLs MICA and MICB are expressed on tumors of epithelial origin in vivo. For the other recently described set of human NKG2DLs, the UL16-binding proteins (ULBPs), expression in vivo is as yet undefined. In this study we investigated expression and function of NKG2DLs in leukemia using a panel of newly generated NKG2DL-specific monoclonal antibodies. We report that leukemia cells from patients variously express MIC and ULBP molecules on the cell surface with MICA most frequently detected. Patient leukemia cells expressing MICA were lysed by NK cells in an NKG2D-dependent fashion. Sera of patients, but not of healthy donors, contained elevated levels of soluble MICA (sMICA). We also detected increased sMICB levels in patient sera using a newly established MICB-specific enzyme-linked immunosorbent assay. Reduction of leukemia MIC surface expression by shedding may impair NKG2D-mediated immune surveillance of leukemias. In addition, determination of sMICA and sMICB levels may be implemented as a prognostic parameter in patients with hematopoietic malignancies.
Similar articles
- Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, Kubin M, Cosman D, Ferrone S, Moretta L, Moretta A. Pende D, et al. Cancer Res. 2002 Nov 1;62(21):6178-86. Cancer Res. 2002. PMID: 12414645 - MICAgen Mice Recapitulate the Highly Restricted but Activation-Inducible Expression of the Paradigmatic Human NKG2D Ligand MICA.
Kim Y, Born C, Bléry M, Steinle A. Kim Y, et al. Front Immunol. 2020 Jun 4;11:960. doi: 10.3389/fimmu.2020.00960. eCollection 2020. Front Immunol. 2020. PMID: 32582150 Free PMC article. - Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
Matusali G, Tchidjou HK, Pontrelli G, Bernardi S, D'Ettorre G, Vullo V, Buonomini AR, Andreoni M, Santoni A, Cerboni C, Doria M. Matusali G, et al. FASEB J. 2013 Jun;27(6):2440-50. doi: 10.1096/fj.12-223057. Epub 2013 Feb 8. FASEB J. 2013. PMID: 23395909 - The UL16-binding proteins, a novel family of MHC class I-related ligands for NKG2D, activate natural killer cell functions.
Sutherland CL, Chalupny NJ, Cosman D. Sutherland CL, et al. Immunol Rev. 2001 Jun;181:185-92. doi: 10.1034/j.1600-065x.2001.1810115.x. Immunol Rev. 2001. PMID: 11513139 Review. - Role of Polymorphisms of NKG2D Receptor and Its Ligands in Acute Myeloid Leukemia and Human Stem Cell Transplantation.
Machuldova A, Holubova M, Caputo VS, Cedikova M, Jindra P, Houdova L, Pitule P. Machuldova A, et al. Front Immunol. 2021 Mar 30;12:651751. doi: 10.3389/fimmu.2021.651751. eCollection 2021. Front Immunol. 2021. PMID: 33868289 Free PMC article. Review.
Cited by
- Unraveling the role of ADAMs in clinical heterogeneity and the immune microenvironment of hepatocellular carcinoma: insights from single-cell, spatial transcriptomics, and bulk RNA sequencing.
Chen J, Yuan Q, Guan H, Cui Y, Fu C, Wei T, Liu K. Chen J, et al. Front Immunol. 2024 Sep 13;15:1461424. doi: 10.3389/fimmu.2024.1461424. eCollection 2024. Front Immunol. 2024. PMID: 39346916 Free PMC article. - CircARAP2 controls sMICA-induced NK cell desensitization by erasing CTCF/PRC2-induced suppression in early endosome marker RAB5A.
Guo F, Du N, Wen X, Li Z, Guo Y, Zhou L, Hoffman AR, Li L, Hu JF, Cui J. Guo F, et al. Cell Mol Life Sci. 2024 Jul 24;81(1):307. doi: 10.1007/s00018-024-05285-1. Cell Mol Life Sci. 2024. PMID: 39048814 Free PMC article. - Blockade of the TIGIT-CD155/CD112 axis enhances functionality of NK-92 but not cytokine-induced memory-like NK cells toward CD155-expressing acute myeloid leukemia.
Seel K, Schirrmann RL, Stowitschek D, Ioseliani T, Roiter L, Knierim A, André MC. Seel K, et al. Cancer Immunol Immunother. 2024 Jul 5;73(9):180. doi: 10.1007/s00262-024-03766-7. Cancer Immunol Immunother. 2024. PMID: 38967649 Free PMC article. - Soluble NKG2DLs Are Elevated in Breast Cancer Patients and Associate with Disease Outcome.
Seller A, Tegeler CM, Mauermann J, Schreiber T, Hagelstein I, Liebel K, Koch A, Heitmann JS, Greiner SM, Hayn C, Dannehl D, Engler T, Hartkopf AD, Hahn M, Brucker SY, Salih HR, Märklin M. Seller A, et al. Int J Mol Sci. 2024 Apr 8;25(7):4126. doi: 10.3390/ijms25074126. Int J Mol Sci. 2024. PMID: 38612935 Free PMC article. - Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16a/NKG2D Immune-Modulating TriNKET® CC-96191.
Lunn-Halbert MC, Laszlo GS, Erraiss S, Orr MT, Jessup HK, Thomas HJ, Chan H, Jahromi MA, Lloyd J, Cheung AF, Chang GP, Dichwalkar T, Fallon D, Grinberg A, Rodríguez-Arbolí E, Lim SYT, Kehret AR, Huo J, Cole FM, Scharffenberger SC, Walter RB. Lunn-Halbert MC, et al. Cancers (Basel). 2024 Feb 22;16(5):877. doi: 10.3390/cancers16050877. Cancers (Basel). 2024. PMID: 38473239 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical